TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10845898

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 541
Study: 9338955

Group type: EXPERIMENTAL
Intervention: Passive longitudinal study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected prevention study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indicated prevention study
Number of subjects: 0
Study: 7679836

Group type: EXPERIMENTAL
Intervention: FK 506/prednisone
Number of subjects: 125

Group type: COMPARATOR
Intervention: FK 506/azathioprine/prednisone
Number of subjects: 125
Study: 3529370

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol) for 8 weeks
Number of subjects: 28
Study: 29887289

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (N2O) inhalation (50% for 30 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrieval with negative PE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrieval with no PE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-alcohol memory retrieval with PE
Number of subjects: 60
Study: 26818420

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin (FL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: S100A12 (FS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) and fecal lactoferrin (FL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and Crohn's Disease Activity Index (CDAI)
Number of subjects: 135
Study: 24836523

Group type: EXPERIMENTAL
Intervention: Organ-specific dose reduction (OSDR) and attenuation-based tube potential selection (ATPS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard protocol (control group)
Number of subjects: 70
Study: 22342007

Group type: EXPERIMENTAL
Intervention: Aspheric Acri.Smart 36A IOL
Number of subjects: 152

Group type: COMPARATOR
Intervention: Spherically neutral Akreos MI60 IOL
Number of subjects: 152

Group type: COMPARATOR
Intervention: Spherical IOLs
Number of subjects: 152

Group type: COMPARATOR
Intervention: Spherically neutral IOLs
Number of subjects: 152

Group type: COMPARATOR
Intervention: Negatively aspheric IOLs (asphericity -0.17 μm)
Number of subjects: 152
Study: 20195613

Group type: EXPERIMENTAL
Intervention: Modeling in value-based medicine (VBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model validation
Number of subjects: 0
Study: 19173919

Group type: EXPERIMENTAL
Intervention: rh-endostatin plus NP chemotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: NP alone
Number of subjects: 57
Study: 15920685

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LR)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 83
Study: 12051882

Group type: EXPERIMENTAL
Intervention: Mitomycin 8 mg/m², Doxorubicin 40 mg/m², Cisplatin 60 mg/m² (MAP chemotherapy)
Number of subjects: 37
Study: 10063926

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 infusion (30 microg/hr)
Number of subjects: 14
Study: 7747698

Group type: EXPERIMENTAL
Intervention: Non-Q-wave acute myocardial infarction (AMI)
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Absence of prior coronary angioplasty
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Duration of pain >= 60 minutes
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: ST-segment deviation on the qualifying electrocardiogram
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Recent-onset angina
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Risk factors for non-Q-wave AMI
Number of subjects: 1473
Study: 2139241

Group type: EXPERIMENTAL
Intervention: McKenzie method of treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patient education in 'mini back school'
Number of subjects: 100
Study: 6105436

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 214
Study: 30734388

Group type: EXPERIMENTAL
Intervention: Wave-CAIPI (9-fold acceleration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GRAPPA (2-4 fold acceleration)
Number of subjects: 30
Study: 27658762

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25416739

Group type: EXPERIMENTAL
Intervention: Functional upper extremity task-specific training (2250 repetitions of simulated feeding with nondominant hand over 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No training
Number of subjects: 50
Study: 23851069

Group type: EXPERIMENTAL
Intervention: Dapagliflozin at doses of 0.3mg and above
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dapagliflozin at doses of 0.1mg and above
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: New OEL for dapagliflozin
Number of subjects: 36
Study: 21415052

Group type: EXPERIMENTAL
Intervention: initial combination therapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: sequential monotherapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: step-up combination therapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: initial combination with prednisone
Number of subjects: 508

Group type: COMPARATOR
Intervention: initial combination with infliximab
Number of subjects: 508
Study: 19105889

Group type: EXPERIMENTAL
Intervention: 2.5 mg vitamin D(2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17339864

Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min before ethanol (0.6 gm/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min after ethanol (0.6 gm/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ethanol (0.6 gm/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 20
Study: 12646332

Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate hydrochloride (LAAM)
Number of subjects: 163
Study: 10967897

Group type: EXPERIMENTAL
Intervention: nCPAP treatment (Group L)
Number of subjects: 102
Study: 9366458

Group type: EXPERIMENTAL
Intervention: Sufentanil (3 microg/kg) administered over 2 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Muscle relaxant (Pancuronium 0.1 mg/kg) administered after sufentanil
Number of subjects: 30
Study: 8378947

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit (n = 124)
Number of subjects: 245

Group type: COMPARATOR
Intervention: General medical wards (n = 121)
Number of subjects: 245
Study: 3460327

Group type: EXPERIMENTAL
Intervention: Busulphan (group 1: n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Combination chemotherapy (VP16‐213 with cytosine arabinoside and doxorubicin) (group 2: n = 10)
Number of subjects: 21
Study: 31729895

Group type: EXPERIMENTAL
Intervention: Sexual arousal condition
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 115
Study: 30859608

Group type: EXPERIMENTAL
Intervention: Apixaban, 2.5 mg x 2/day for 6 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 104
Study: 28183863

Group type: EXPERIMENTAL
Intervention: Light-Intensity with Blood Flow Restriction (LI+BFR) during leg-press
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light-Intensity with Blood Flow Restriction (LI+BFR) during treadmill exercise
Number of subjects: 0
Study: 25586270

Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion (Hb < 9.7 g/dL; < 6 mmol/L)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Liberal RBC transfusion (Hb < 11.3 g/dL; < 7 mmol/L)
Number of subjects: 284
Study: 23672735

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided drainage (USD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Surgical incision and drainage (I&D)
Number of subjects: 17
Study: 21851929

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 126
Study: 19372341

Group type: EXPERIMENTAL
Intervention: Colloid preload (15 mL/kg hydroxyethyl starch (HES) 130/0.4 [Voluven 6%])
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coload (given when cerebrospinal fluid identified)
Number of subjects: 40
Study: 16583194

Group type: EXPERIMENTAL
Intervention: PEG-C preparation (polyethylene glycol solution plus contrast medium)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PEG preparation (polyethylene glycol solution)
Number of subjects: 100
Study: 15340345

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 11489000

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) and Carboplatin (AUC 5)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m2 in 3 h) and Carboplatin (AUC 5)
Number of subjects: 1077
Study: 9516568

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% glucose (control)
Number of subjects: 60
Study: 8041980

Group type: EXPERIMENTAL
Intervention: Clonidine 0.005 mg/kg p.o.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lorazepam 0.03 mg/kg p.o.
Number of subjects: 30
Study: 2656310

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg capsules three times weekly orally
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gestrinone 5.0 mg capsules twice weekly orally
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg vaginal tablets three times weekly
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous treatment for 24 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Discontinuation at 1 year
Number of subjects: 100
Study: 29899047

Group type: EXPERIMENTAL
Intervention: Telephone health coaching intervention delivered by nurses (4 sessions over 11 weeks)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Usual care (leaflet about COPD)
Number of subjects: 577
Study: 28436307

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 640

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 640
Study: 26286593

Group type: EXPERIMENTAL
Intervention: Sensorimotor training 2 times per week
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sensorimotor training 4 times per week
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sensorimotor training 6 times per week
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study: 23547490

Group type: EXPERIMENTAL
Intervention: Colgate Great Regular Flavor (0.83% MFP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Crest Pro‐Health (0.454% SnF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Colgate Total Clean Mint Toothpaste (0.3% triclosan/copolymer/0.22% NaF)
Number of subjects: 32
Study: 21742096

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17800
Study: 19854539

Group type: EXPERIMENTAL
Intervention: Naabak(R) eyedrops (preservative-free NAAGA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Larmabak(R))
Number of subjects: 0
Study: 16732083

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (50 microg/kg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (10 microg/kg)
Number of subjects: 350
Study: 15623588

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (TXT q 3w)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m2 days 1, 8, 15, 22, and 29 every 6 weeks + prednisone 5 mg twice a day for a total of 5 cycles (TXT qw)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Mitoxantrone 12 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles (MTZ q 3w)
Number of subjects: 1006
Study: 11717659

Group type: EXPERIMENTAL
Intervention: Presumptive sexually transmitted disease treatment during pregnancy
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Iron/folate and referral for syphilis (control)
Number of subjects: 4033
Study: 9158077

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (Premarin 0.625 mg and Norgestrel 1 mg) for more than 1 year
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (51 untreated postmenopausal women)
Number of subjects: 97
Study: 8198022

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day plus bezafibrate 400 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day plus bezafibrate 400 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fluvastatin plus bezafibrate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg/day plus cholestyramine 8 g/day
Number of subjects: 34
Study: 3294021

Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily + Bendrofluazide 5 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg daily + Verapamil 160 mg twice daily
Number of subjects: 20
Study: 31719072

Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration, treated for 6 months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine extract (CBME)
Number of subjects: 30
Study: 28767525

Group type: EXPERIMENTAL
Intervention: Lower Limb (LL) exercises
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional lumbar extensor (LE) exercises
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lumbar stabilization (LS) exercises
Number of subjects: 84
Study: 25111038

Group type: EXPERIMENTAL
Intervention: Cord drainage (unclamped after cutting)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control (cord left clamped)
Number of subjects: 485
Study: 24130585

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (with S. calva root extract)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Herbal Dentifrice (Arodent™)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Synthetic Dentifrice (Colgate®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Dentifrice
Number of subjects: 80
Study: 17012531

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) self-management booklet
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Symptom control (SC) self-management booklet
Number of subjects: 360

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 360
Study: 12598435

Group type: EXPERIMENTAL
Intervention: Screening and prophylactic treatment (measurement of anterior chamber depth and intraocular pressure, followed by laser iridotomy for those with occludable angles)
Number of subjects: 4725

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 4725
Study: 10407201

Group type: EXPERIMENTAL
Intervention: Repeated stimulus presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulus duration
Number of subjects: 0
Study: 7552933

Group type: EXPERIMENTAL
Intervention: Loratadine, 20 mg once daily for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 35
Study: 1664832

Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg once daily
Number of subjects: 278

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 278
Study: 7194172

Group type: EXPERIMENTAL
Intervention: 30 microgram ethinyl oestradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 microgram ethinyl oestradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triphasic formulation (ethinyl oestradiol and levonorgestrel)
Number of subjects: 0
Study: 29874478

Group type: EXPERIMENTAL
Intervention: Exercise at 30 °C/40% RH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise at 20 °C/40% RH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive heat exposure at 30 °C/40% RH
Number of subjects: 12
Study: 28466851

Group type: EXPERIMENTAL
Intervention: Parental BMI (paternal and maternal)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Paternal BMI
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Parental BMI
Number of subjects: 307
Study: 26614481

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1063
Study: 23130817

Group type: EXPERIMENTAL
Intervention: Vitamin BC capsules plus corresponding deficient hematinics (for groups I, II, III, IV)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vitamin BC capsules only (for group V)
Number of subjects: 91
Study: 20947926

Group type: EXPERIMENTAL
Intervention: Intra-peritoneal paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18325887

Group type: COMPARATOR
Intervention: Normal saline (Group 1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microg kg(‐1) (Group 2)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 microg kg(‐1) (Group 3)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 microg kg(‐1) (Group 4)
Number of subjects: 165
Study: 15569851

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: NT-proBNP and CRP screening together
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: NT-proBNP > 50 pmol/L and CRP > 0.84 mg/L
Number of subjects: 258
Study: 12783696

Group type: EXPERIMENTAL
Intervention: Mifepristone (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: D & C (Control group, n = 10)
Number of subjects: 20
Study: 10369709

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (20 g free glutamine replacing 3.8 g of total nitrogen)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard feeds (without glutamine)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard feeds
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation in surgical patients
Number of subjects: 168
Study: 8763084

Group type: EXPERIMENTAL
Intervention: Subunit vaccine injected into the buttock or internal aspect of the thigh
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Inactivated whole-virus vaccine
Number of subjects: 1959

Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 1959
Study: 1868502

Group type: EXPERIMENTAL
Intervention: Captopril (37.5-75 mg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ibopamine (150-300 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 7066142

Group type: EXPERIMENTAL
Intervention: Methohexitone alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methohexitone with fentanyl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Althesin alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etomidate with fentanyl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Althesin with fentanyl
Number of subjects: 100
Study: 30556939

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol (FP/SAL)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Fluticasone (FP)
Number of subjects: 300
Study: 28975718

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg (increased to 80 mg if serum UA level was ≥6.0 mg/dl on day 14)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 24718916

Group type: EXPERIMENTAL
Intervention: Unsupported sitting with eyes open
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unsupported sitting with eyes closed
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standing position with eyes open
Number of subjects: 14
Study: 24341437

Group type: EXPERIMENTAL
Intervention: Consistent and positive parental disciplinary practices
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Children with siblings and from single-parent families
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Children from two-parent families
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Children with better bimanual performance
Number of subjects: 48
Study: 22583875

Group type: EXPERIMENTAL
Intervention: A/V glasses
Number of subjects: 48

Group type: COMPARATOR
Intervention: No distraction
Number of subjects: 48
Study: 19221871

Group type: EXPERIMENTAL
Intervention: Community-based treatment (COMM)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Clinic-based treatment (CLINIC)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Healthy control children
Number of subjects: 139
Study: 17451369

Group type: EXPERIMENTAL
Intervention: Teriparatide treatment
Number of subjects: 57
Study: 15199353

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training for 3 months (G1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (G2)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Detraining after 3 months of training (G1)
Number of subjects: 52
Study: 11771983

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg, i.v.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glycopyrrolate (0.2 mg, i.v.)
Number of subjects: 9
Study: 9525445

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Budesonide 3200 microg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64